Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 310-316

  Yi, Hee ^a   Cho, Hee Jung ^a   Cho, Soo Min ^a   Jo, Kyul ^a   Park, Jin A ^a   Kim, Na Hyun ^a   Amidon, Gordon L ^b   Kim, Jin Suk ^a   Shin, Ho Chul ^a  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer stem cell; H460; Interleukin 6 receptor; Lung cancer; Sphere

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CELL RENEWAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

ANTIBODIES, NEUTRALIZING; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FLUOROURACIL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; METHOTREXATE; NEOPLASTIC STEM CELLS; RECEPTORS, INTERLEUKIN-6; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; UP-REGULATION;

EID: 84862902822     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1447     Document Type: Article

References (42)

1. Reyxa T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
2. Ponti D, Costa A, Zaffaroni N, et al: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511, 2005. (Pubitemid 40911148)
3. Pardal R, Clarke MF and Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902, 2003. (Pubitemid 37500174)
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
5. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004. (Pubitemid 39551674)
6. Collins AT and Maitland NJ: Prostate cancer stem cells. Eur J Cancer 42: 1213-1218, 2006. (Pubitemid 43795097)
7. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007. (Pubitemid 47355323)
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007. (Pubitemid 46067311)
9. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008. (Pubitemid 351267301)
10. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.
11. Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004. (Pubitemid 39305058)
12. Kim M, Turnquist H, Jackson J, et al: The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 22-28, 2002. (Pubitemid 34101455)
13. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM and Isaacs JT: The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68: 9703-9711, 2008.
14. Dontu G, Abdallah WM, Foley JM, et al: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003. (Pubitemid 36583168)
15. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206, 2002.
16. Levina V, Marrangoni A, Wang T, et al: Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 70: 338-346, 2010.
17. Tirino V, Camerlingo R, Franco R, et al: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453, 2009.
18. Xin L, Lukacs RU, Lawson DA, Cheng D and Witte ON: Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 25: 2760-2769, 2007. (Pubitemid 350127860)
19. Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556, 2000. (Pubitemid 30339210)
20. Jee SH, Chu CY, Chiu HC, et al: Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 123: 1169-1175, 2004.
21. Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512, 2005. (Pubitemid 41540626)
22. Tchirkov A, Khalil T, Chautard E, et al: Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96: 474-476, 2007. (Pubitemid 46215219)
23. Gao SP, Mark KG, Leslie K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007. (Pubitemid 350224094)
24. Kudo M, Jono H, Shinriki S, et al: Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg 111: 219-225, 2009.
25. Shinriki S, Jono H, Ota K, et al: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15: 5426-5434, 2009.
26. Wang H, Lathia JD, Wu Q, et al: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404, 2009.
27. Seo DC, Sung JM, Cho HJ, et al: Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 6: 75, 2007.
28. Sung JM, Cho HJ, Yi H, et al: Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371: 163-167, 2008.
29. Sullivan JP, Minna JD and Shay JW: Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29: 61-72, 2010.
30. Ku HH, Chen YC, Hsu HS, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637, 2008.
31. Sozzi G, Bertolini G, Roz L, et al: Highly tumorigenic lung cancer CD133(+) cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.
32. Wu CW, Chiou SH, Wang ML, et al: Coexpression of Oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70: 10433-10444, 2010.
33. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005. (Pubitemid 40488633)
34. Novick D, Engelmann H, Wallach D and Rubinstein M: Soluble cytokine receptors are present in normal human urine. J Exp Med 170: 1409-1414, 1989. (Pubitemid 19250702)
35. Jones SA, Horiuchi S, Topley N, Yamamoto N and Fuller GM: The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15: 43-58, 2001. (Pubitemid 32061655)
36. Salgado R, Junius S, Benoy I, et al: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646, 2003. (Pubitemid 36091468)
37. Wu CW, Wang SR, Chao MF, et al: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91: 1417-1422, 1996. (Pubitemid 26236381)
38. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A and Catalano G: Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649-652, 1998.
39. Chung YC, Hsu CP, Chen YL, et al: Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest 41: 277-284, 2011.
40. Nishimoto N, Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A and Curiel DT: Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 67: 871-875, 2007.
41. Ogata A, Chauhan D, Teoh G, et al: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159: 2212-2221, 1997. (Pubitemid 127681011)
42. Fukada T, Hibi M, Yamanaka Y, et al: Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5: 449-460, 1996. (Pubitemid 26423473)